Sign In
Buy DRTS
$12.71
-0.270 (-2.08%)
At Close: Jul 10, 2026
New Strong Sell Stocks for July 7th
09:36am, Tuesday, 07'th Jul 2026
AMPX, DRTS and BELFB have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2026.
New Strong Sell Stocks for July 2nd
04:50am, Thursday, 02'nd Jul 2026
DRTS, CANG and LAZ have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2026.
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah Medical Center in Israel
Alpha Tau Medical: A Lot Of Shots On Goal
08:13am, Friday, 12'th Jun 2026
Alpha Tau Medical (DRTS) is pioneering localized alpha particle radiation for solid tumors, with strong recent clinical and partnership momentum. DRTS's innovative and patented "Alpha DaRT" technology
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Trial and Add Two U.S. Sites; Early Interim Results Showed 100% Local Disease Control
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
08:30am, Wednesday, 03'rd Jun 2026
- Joint partnership leverages Alpha Tau's highly potent, localized alpha-radiation technology and Tolmar's commercial leadership to transform the U.S. uro-oncology landscape - Collaboration elevates
- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of thre
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
09:04am, Friday, 29'th May 2026
Alpha Tau Medical NASDAQ: DRTS outlined a series of clinical and regulatory updates during the Lytham Partners Spring 2026 Investor Conference, with Raphi Levy of Alpha Tau telling investors the compa
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
04:01pm, Monday, 18'th May 2026
- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion of pat
Alpha Tau to Participate in May Investor Conferences
08:30am, Monday, 18'th May 2026
JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT�
Alpha Tau Medical Stock Surges As Interim Brain Tumor Trial Data Sparks Rally
12:06pm, Monday, 11'th May 2026
Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) rose Monday after the company reported interim results from its U.S. trial of Alpha DaRT in patients with recurrent glioblastoma.
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
10:09am, Monday, 11'th May 2026
Alpha Tau Medical NASDAQ: DRTS presented early clinical results from the first three patients treated in its REGAIN study of Alpha DaRT for recurrent glioblastoma, with company executives and clinical
- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total disappearance of all enhancing tumor lesions, per multiple MRI scans since
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
09:10am, Friday, 08'th May 2026
JERUSALEM, May 08, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT
